<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066413</url>
  </required_header>
  <id_info>
    <org_study_id>Stardust</org_study_id>
    <nct_id>NCT04066413</nct_id>
  </id_info>
  <brief_title>Growth and Tolerance Trial on Infant Formula With HMO</brief_title>
  <acronym>Stardust</acronym>
  <official_title>Growth and Tolerance Trial in Healthy Infants on Infant Formula Supplemented With a Human Milk Oligosaccharide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FrieslandCampina</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FrieslandCampina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to compare growth of healthy infants fed an infant formula&#xD;
      supplemented with a human milk oligosaccharide to that of infants on standard formula.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2019</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Growth</measure>
    <time_frame>From enrollment until end of the 3 month-study</time_frame>
    <description>Infant growth measured as body weight gain per day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>Infant weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recumbent length</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>Infant length (cm and cm/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head circumference</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>Head circumference (cm and cm/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry z-scores</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>World Health Organization (WHO) growth standard calculated z-scores for weight, length, weight-for-length and head circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Formula tolerance</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>Parents are asked to keep a diary on formula intake 3 days prior to each monthly study visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastro-intestinal comfort</measure>
    <time_frame>Monthly, from enrollment until end of the 3 month-study</time_frame>
    <description>Parents are asked to keep a diary 3 days prior to each monthly study visit including questions on gastro-intestinal symptoms (e.g. cramps, constipation, vomiting) and crying behavior</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">279</enrollment>
  <condition>Healthy Growth</condition>
  <arm_group>
    <arm_group_label>Breastfed group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-randomized breastfed reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group receiving standard infant formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formula with HMO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group receiving standard infant formula supplemented with HMO</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard infant formula</intervention_name>
    <description>Standard infant formula</description>
    <arm_group_label>Control formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infant formula supplemented with HMO</intervention_name>
    <description>Infant formula supplemented with HMO</description>
    <arm_group_label>Formula with HMO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age ≥ 37 weeks&#xD;
&#xD;
          -  Birth weight ≥ 2500 grams&#xD;
&#xD;
          -  No recognized diseases (such as cardiac, pulmonary, gastrointestinal, renal or genetic&#xD;
             diseases)&#xD;
&#xD;
          -  Boys and girls&#xD;
&#xD;
          -  Recruited &lt; 1 month/age&#xD;
&#xD;
          -  Being available for follow up until the age of 4 months&#xD;
&#xD;
          -  Exclusive formula feeding or exclusive breast feeding at time of recruitment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gestational age &lt;37 weeks&#xD;
&#xD;
          -  Birth weight &lt;2500 grams&#xD;
&#xD;
          -  Severe acquired or congenital diseases, mental or physical disorders&#xD;
&#xD;
          -  Illness at screening/ inclusion&#xD;
&#xD;
          -  Incapability of parents/caregivers to comply with the study protocol&#xD;
&#xD;
          -  Received antibiotics within the first month of life&#xD;
&#xD;
          -  Not tolerating standard cow's milk based infant formula&#xD;
&#xD;
          -  Participation in another clinical trial&#xD;
&#xD;
          -  Maternal illicit drug use during pregnancy or post-partum period&#xD;
&#xD;
          -  Parent/caregiver does not have a cell phone to use for filling out questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Month</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dianne Delsing, PhD</last_name>
    <phone>+31653598111</phone>
    <email>dianne.delsing@frieslandcampina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inge Thijs-Verhoeven, MSc</last_name>
    <phone>+31613248135</phone>
    <email>Inge.Thijs-Verhoeven@frieslandcampina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James E Heubi, MD, Prof</last_name>
      <phone>513-636-9776</phone>
      <email>James.Heubi@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Andre Hawkins, MSc</last_name>
      <email>Andre.Hawkins@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>James E Heubi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>infant formula</keyword>
  <keyword>human milk oligosaccharide</keyword>
  <keyword>HMO</keyword>
  <keyword>growth</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

